Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China
· Delayed Price · Currency is CNY 16.25
-0.03 (-0.18%)
Jun 27, 2025, 3:04 PM CST
Hybio Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 706.92 | 547.2 | 383.13 | 692.29 | 730.93 | 714.01 | Upgrade
|
| Other Revenue | 43 | 43 | 48.25 | 12.03 | 5.04 | 7.71 | Upgrade
|
| Revenue | 749.91 | 590.2 | 431.38 | 704.32 | 735.97 | 721.72 | Upgrade
|
| Revenue Growth (YoY) | 84.97% | 36.81% | -38.75% | -4.30% | 1.97% | 17.51% | Upgrade
|
| Cost of Revenue | 350.16 | 281.47 | 260.42 | 194.83 | 271.88 | 153.54 | Upgrade
|
| Gross Profit | 399.75 | 308.73 | 170.97 | 509.49 | 464.1 | 568.18 | Upgrade
|
| Selling, General & Admin | 249.07 | 240.13 | 367.6 | 484.36 | 545.43 | 536.99 | Upgrade
|
| Research & Development | 90.03 | 87.33 | 159.6 | 154.79 | 101.94 | 140.21 | Upgrade
|
| Other Operating Expenses | 11.58 | 8.13 | 12.22 | 16.52 | 16.78 | 11.72 | Upgrade
|
| Operating Expenses | 356.66 | 341.14 | 542.38 | 691.62 | 734.37 | 1,113 | Upgrade
|
| Operating Income | 43.09 | -32.41 | -371.41 | -182.13 | -270.27 | -545.25 | Upgrade
|
| Interest Expense | -105.58 | -106.5 | -120.46 | -103.25 | -87.92 | -59.24 | Upgrade
|
| Interest & Investment Income | 1.9 | 1.9 | 0.22 | 0.57 | 391.46 | 18.86 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.64 | 3.64 | 0.29 | 1.64 | -1.55 | -4.37 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.51 | -10.45 | -11.2 | -10.01 | -16.22 | -9.41 | Upgrade
|
| EBT Excluding Unusual Items | -58.47 | -143.82 | -502.57 | -293.18 | 15.48 | -599.41 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.42 | - | 34.71 | -89.77 | -16.47 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 42.1 | 42.78 | -0.51 | 3.41 | 35.2 | -0.95 | Upgrade
|
| Asset Writedown | -84.88 | -82.43 | -90.81 | -17.51 | -41.99 | -10.86 | Upgrade
|
| Legal Settlements | - | - | - | - | -1.24 | - | Upgrade
|
| Other Unusual Items | 25.2 | 21.06 | 48.08 | 24.24 | 42.71 | 22.99 | Upgrade
|
| Pretax Income | -76.47 | -162.41 | -511.1 | -372.81 | 33.68 | -588.24 | Upgrade
|
| Income Tax Expense | 19.84 | 17.68 | 4.34 | -0.27 | 5.24 | 21.06 | Upgrade
|
| Earnings From Continuing Operations | -96.3 | -180.09 | -515.44 | -372.55 | 28.44 | -609.3 | Upgrade
|
| Minority Interest in Earnings | 6.62 | 6.44 | 1.57 | 2 | 2.37 | -0.13 | Upgrade
|
| Net Income | -89.68 | -173.65 | -513.88 | -370.55 | 30.81 | -609.43 | Upgrade
|
| Net Income to Common | -89.68 | -173.65 | -513.88 | -370.55 | 30.81 | -609.43 | Upgrade
|
| Shares Outstanding (Basic) | 910 | 868 | 886 | 882 | 1,027 | 923 | Upgrade
|
| Shares Outstanding (Diluted) | 910 | 868 | 886 | 882 | 1,027 | 923 | Upgrade
|
| Shares Change (YoY) | 9.72% | -2.00% | 0.42% | -14.09% | 11.21% | 0.19% | Upgrade
|
| EPS (Basic) | -0.10 | -0.20 | -0.58 | -0.42 | 0.03 | -0.66 | Upgrade
|
| EPS (Diluted) | -0.10 | -0.20 | -0.58 | -0.42 | 0.03 | -0.66 | Upgrade
|
| Free Cash Flow | 57.76 | 48.87 | -85.3 | -174.04 | -42.17 | -195.67 | Upgrade
|
| Free Cash Flow Per Share | 0.06 | 0.06 | -0.10 | -0.20 | -0.04 | -0.21 | Upgrade
|
| Gross Margin | 53.31% | 52.31% | 39.63% | 72.34% | 63.06% | 78.72% | Upgrade
|
| Operating Margin | 5.75% | -5.49% | -86.10% | -25.86% | -36.72% | -75.55% | Upgrade
|
| Profit Margin | -11.96% | -29.42% | -119.12% | -52.61% | 4.19% | -84.44% | Upgrade
|
| Free Cash Flow Margin | 7.70% | 8.28% | -19.77% | -24.71% | -5.73% | -27.11% | Upgrade
|
| EBITDA | 188.31 | 113.52 | -222.64 | -52.6 | -144.93 | -440.71 | Upgrade
|
| EBITDA Margin | 25.11% | 19.23% | -51.61% | -7.47% | -19.69% | -61.06% | Upgrade
|
| D&A For EBITDA | 145.22 | 145.93 | 148.77 | 129.53 | 125.35 | 104.54 | Upgrade
|
| EBIT | 43.09 | -32.41 | -371.41 | -182.13 | -270.27 | -545.25 | Upgrade
|
| EBIT Margin | 5.75% | -5.49% | -86.10% | -25.86% | -36.72% | -75.55% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 15.57% | - | Upgrade
|
| Revenue as Reported | 749.91 | 590.2 | 431.38 | 704.32 | 735.97 | 721.72 | Upgrade
|
Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.